Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Expected to Announce Quarterly Sales of $290,000.00
Wall Street analysts expect Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) to post sales of $290,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Galmed Pharmaceuticals’ earnings. The lowest sales estimate is $280,000.00 and the highest is $300,000.00. The company is scheduled to issue its next quarterly earnings report on Wednesday, August 2nd.
On average, analysts expect that Galmed Pharmaceuticals will report full year sales of $290,000.00 for the current year, with estimates ranging from $1.09 million to $1.20 million. For the next financial year, analysts anticipate that the business will report sales of $550,000.00 per share. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Galmed Pharmaceuticals.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.13. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.29 million.
GLMD has been the topic of a number of recent research reports. Maxim Group set a $9.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 15th. HC Wainwright cut their price target on shares of Galmed Pharmaceuticals from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, March 28th. ValuEngine upgraded shares of Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 17th. Finally, Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research note on Tuesday, March 28th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.56.
A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. KCG Holdings Inc. purchased a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned about 0.17% of Galmed Pharmaceuticals at the end of the most recent quarter. 8.02% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Expected to Announce Quarterly Sales of $290,000.00” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/16/galmed-pharmaceuticals-ltd-nasdaqglmd-expected-to-announce-quarterly-sales-of-290000-00.html.
Galmed Pharmaceuticals (GLMD) opened at 6.85 on Friday. The company’s market capitalization is $83.35 million. Galmed Pharmaceuticals has a one year low of $2.78 and a one year high of $7.09. The firm’s 50-day moving average is $5.40 and its 200 day moving average is $4.69.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.